The Solid Tumor Profile is designed to analyze the molecular abnormalities of DNA in various solid tumors including cancers of the lung, pancreas, brain, colon, breast, ovary, endometrium, thyroid, head and neck, and soft tissue (sarcoma and GIST). GTC always recommends adding RNA analysis to our Solid Tumor Profile to provide a complete answer. RNA helps provide additional clinically actionable information on fusions, gene expression, mutations immunophenotyping, and more.
The Solid Tumor Profile provides physicians with clinically actionable information. This profiling covers abnormalities in single-nucleotide and indels in 434 genes. All exons of the 434 genes are covered and evaluated for abnormalities. In addition, the test is designed to detect microsatellite instability (MSI), tumor mutation burden (TMB) and homologous recombination deficiency (HRD). Significant amplification in various genes can also be detected and reported. The provided information helps in determining prognosis, designing a therapeutic approach and predict response to therapy.
Turn Around Time: 5-7 days
How to complete the Genomic Testing Cooperative requisition form.
Keep in mind that we do not accept blood samples directly from individuals. Talk with your M.D. to fill out the form for you.